To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

February 27, 2019

Today's Rundown

Featured Story

Blackstone, Novartis found cardiovascular startup with $250M

Blackstone Life Sciences has committed $250 million to create a cardiovascular startup with Novartis. The biotech, Anthos Therapeutics, begins life with an anti-factor XI antibody that Novartis took to the cusp of phase 2 as an antithrombotic therapy.

Top Stories

Sarepta pulls the trigger on $165M Myonexus buy

Sarepta expanded into limb-girdle muscular dystrophy last May, when it ponied up $60 million to license five gene therapies and snag an option to acquire the French company. Now, it's buying Myonexus and its pipeline outright for $165 million.

Servier terminates CTI cancer pact following clinical failure

Servier has terminated its Pixuvri collaboration agreement with CTI BioPharma. The action comes seven months after the B-cell non-Hodgkin lymphoma drug failed a key clinical trial.

[Sponsored] Rise in Targeted Therapies Drives Need for Flexible, Small-Volume Manufacturing

Biologics have experienced steady double-digit growth over the last 15 years and now comprise slightly more than a quarter of all New Molecular Entity (NME) FDA approvals.

CytomX slumps as BMS bails on 3 partnered projects

Amid an R&D update from CytomX is the news that partner Bristol-Myers Squibb has dropped three programs, putting pressure on the biotech's share price.

Sellas mulling ‘strategic options’ to stay afloat, including sale

Sellas Life Sciences is considering a number of “strategic options” to make sure it can fund its current plan of developing its leading oncology assets, a pair of cancer vaccines.

Parexel, on a hiring spree, nabs another key FDA staffer as it bolsters oncology executives

Not content with hiring four former FDA staffers this month, Parexel is at it again, nabbing another top ex-FDA executive and promoting a former medical oncologist to boost its cancer drug development services.

Resources

[Research] Maximize Pharma Marketing ROI with Digital HCP Engagement

Which HCP Touchpoints and channels are yielding the best results in today’s digital world?

[Whitepaper] Cell-Based Cancer Immunotherapies: Commercial Risk, Curative Reward

White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each.

[Whitepaper] Better Market Intelligence With Smart Search

It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies.

[Whitepaper] Managing Demand Uncertainty in Biologics Production

When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables.

[Whitepaper] RTSM/IRT: A Roadmap For Developing Systems That Address Current Frustrations

92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper.

[Whitepaper] Six API Challenges That could be Slowing your Development

Download this whitepaper to learn more.

[Whitepaper] Engaging Organized Customers in the Era of the Quadruple Aim

Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim

[Whitepaper] Clinical Validation of a Powerful Immune Assay for Patient Selection

Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens.

[Whitepaper] Host Cell Protein Analysis in Biologic Drug Development

This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis.

[Whitepaper] Integrating clinical research at the Point of Care—A New Operating Model

Clinical trials take too long and cost too much—here's what needs to change.

[Whitepaper] Accelerate Time To Market Working With Industry Specialist MSP

With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market.

[Survey] Veeva 2019 Unified Clinical Operations Survey

Share your thoughts on the life sciences industry's progress in improving study execution.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events